Precision NanoSystems GenVoy-ILM T Cell Kit for mRNA

Click2Contact

The rapid development of COVID-19 vaccines using lipid nanoparticles (LNP) to encapsulate mRNA has demonstrated the power of LNP technology. This novel approach has opened up opportunities for the manufacture of gene-edited cell therapies and in vivo gene targeting.

The GenVoy-ILM T Cell Kit for mRNA is a cell therapy reagent optimised for the delivery of mRNA into activated primary human T cells. Using LNPs designed to exploit endogenous uptake pathways, the method efficiently delivers mRNA into activated human primary T cells to mediate titratable, uniform protein expression levels with high cell viability. The kit enables a high proportion of T cells to be engineered, which should make it a more potent gene delivery method than electroporation.

Preparing mRNA-LNPs from the GenVoy-ILM T Cell Kit for mRNA is quick and simple. Formulated on the NanoAssemblr Spark instrument and cartridges, one preparation takes under 5 min to prepare. The resulting mRNA-LNPs are also compatible with established T cell culture media, allowing rapid integration into existing workflows.

The combination of non-disruptive mRNA delivery technology and seamless integration with cell culture protocols eliminates cell recovery times post-treatment to accelerate the production of T cell therapies.

For more information: https://www.precisionnanosystems.com/platform-technologies/genvoy-platform/t-cell-kit-for-mrna.